No Data
No Data
CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial
CG Oncology's Cretostimogene Shows 75% Response Rate In Bladder Cancer Study, Stock Up
CG Oncology's Promising Phase 3 Trial Results Revealed
CG Oncology Says 75.5% of Patients Achieve CR in Phase 3 Study of Cretostimogene
Express News | CG Oncology Inc -Median Duration of Response Exceeds 28 Months and Is Ongoing
Express News | CG Oncology Inc - Announces 75.5% Complete Response Rate in Phase 3 Study